How Technological Innovation May Transform Alzheimer’s Diagnosis

Each year, we celebrate World Alzheimer’s Day on September 21, hoping that every passing day brings us one step closer to a cure. Alzheimer’s disease is a progressive ailment that destroys an individual’s memory and other important mental functions. Researchers believe that the disease may be caused by an abnormal buildup of proteins around and in brain cells. In its late stage, the disease causes individuals to lose their ability to carry on conversations and respond to their environments.

With new cases of the disease developing every three seconds, it becomes even more important to diagnose and treat this disease in its earlier stages. The role of technological innovation in doing so will be crucial in improving the lives of individuals living with the disease as well as transforming brain health.

After decades of research, investigators are closer than ever to major diagnostic advances in Alzheimer’s disease that could possibly transform the prospects and lives of millions of individuals across the globe. Researchers have developed effective tests based on ground-breaking psychometric analysis, digital health technology and biomarkers, which may help solve the issues physicians face in diagnosing Alzheimer’s. This significant progress also brings the possibility of more effective treatment from new therapies and prevention even closer to reality.

As the global population grows older, Alzheimer’s may soon reach epidemic proportions. This is despite the fact that the condition was first identified more than a century ago by Alois Alzheimer, a German physician.

Diagnosing the disease reliably in its early stages is still a challenge today. For the disease to be diagnosed, various tests have to be conducted by specialists, including neurologists, geriatricians, psychologists, psychiatrists and primary physicians. These tests are usually supplemented by medical imaging of a patient’s brain, i.e., MRIs, PET and CT scans, etc. An individual’s cognitive abilities are also tested at memory clinics through the use of questionnaires, which are considered to be out-of-date with regard to the frame of reference.

These procedures are usually expensive and unavailable in most nations with health inequalities, which means that few individuals have access to them. As a result, most patients are diagnosed with Alzheimer’s when the disease has progressed into its late stage.

However, an increase in the use of digital health may change this. Digital health utilizes the capabilities of data analytics, machine learning and artificial intelligence to develop diagnostic tools that are more accurate and provide more reliable results.

Many companies, including Brain Scientific Inc. (OTCQB: BRSF), have also focused on developing technology to revolutionize brain diagnostics, and results are already showing in the form of faster, more-affordable diagnostic tools.

NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.